Compare GSK plc (GSK) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares International Treasury Bond ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while iShares International Treasury Bond ETF trades at $39.74 (market cap $1.30B). The key difference: GSK plc is far larger — about 70.7× iShares International Treasury Bond ETF's market cap, and GSK plc pays a 3.9% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares International Treasury Bond ETF for 92 Days on average.
| GSK | IGOV | |
|---|---|---|
Market Cap | $91.88B | $1.30B |
Volume | 7,730,529 | 693,740 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $42.99 |
52-Week Low | $43.24 | $39.65 |
Typical Hold Time | 93 Days | 92 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
IGOV trades at $39.73, up 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. Key financial ratios such as P/E and P/S are not available in the provided data. Recent news highlights rising global bond yields, which may impact interest-rate-sensitive assets.
The outlook remains cautious due to bearish technicals and macroeconomic pressures from higher yields. Investment opportunities hinge on undisclosed fundamentals, while risks include market volatility and interest rate sensitivity. Investors should await clearer financial disclosures for a full assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
